5
To maximize the absorption of lumefantrine, AL was given with ~40 millilitres of soya milk, 101 containing an equivalent of 1.2g of fat. The first dose of AL in ART participants was timed to 102 coincide with the next scheduled dose of the antiretroviral drugs.
104
Study population 105
The study population for step 1 and step 2 were HIV infected male and non-pregnant female 106 adults aged ≥18 years residing in Blantyre, Malawi or neighbouring districts of Thyolo and 107 Chiradzulu. Individuals on ART were eligible to participate if they had been on NNRTI or PI-108 based ART for ≥ 6 months and had CD4 cell count ≥ 250 cells/mm 3 . At the beginning of the 109 study, HIV infected antiretroviral naive individuals were eligible if they had CD4 cell count ≥ 110 250/mm 3 but this cut-off point was changed to ≥350/mm 3 when the WHO criteria for ART 111 initiation changed in July 2011. Other inclusion criteria were body weight ≥40kgs, willingness to 112 be admitted in the hospital for 3 days, to remain within the study sites and to be contacted at 113 home or by phone during the course of the study.
115
We excluded subjects who had a body mass index of <18.5kg/m 2 , haemoglobin concentration of 116 <10 g/dL (subsequently changed to <8.5 g/dL based on DSMB recommendation), reported use 117 of any antimalarial drugs within the preceding 4 weeks, reported hypersensitivity to any of the 118 ACTs , receipt of other drugs which are known inhibitors or inducers of P450 enzymes or P-119 glycoprotein (except cotrimoxazole prophylaxis which was standard of care for HIV infected 120 individuals), a history of regular intake of alcohol (>twice/week), tobacco (>3 times/week) or any 121 use of illicit drugs, history or evidence of pre-existing liver, kidney or heart disease, including 122 conductive abnormalities on electrocardiographs (QTc interval>450ms in men and >470ms in 123 females), clinical and/or laboratory evidence of Pf malaria, hepatitis B, pneumonia, tuberculosis, 124 bacteremia, laboratory evidence of potentially life threatening white blood cell disorders such as 125 absolute neutrophil count <0.500*10 9 /L, absolute lymphocyte count <0.35*10 9 /L or absolute 6 platelet count <25*10 9 /L, Karnofsky score of <80% or concurrent participation in any other 127 clinical trial.
129
Sample size
130
The sample size in step 1 was 6 in each of the AL/ART and control (ART-naive) and this was 131 based on standard practice in early PK studies of antimalarial drugs which aim to safeguard the 132 safety of study subjects and minimize the number of subjects who may be potentially exposed 133 to harmful drug levels. In step 2, the sample size was 15 per group which had at least 90% 134 power to detect a two-fold increase in lumefantrine AUC in any of the AL/ART groups compared 135 with the ART-naive group, assuming a mean (standard deviation) lumefantrine AUC of 0.561 136 (0.36) μg/mL/hr (15) in the ART-naive group, at the level of significance of 5%. 
145
Results from screening procedures were available within seven days of screening. Based on 146 these results, potential study participants were informed of their eligibility to participate in the 147 study. Thereafter, research nurses or clinicians sought written informed consent from eligible 148 subjects to participate in the study. Consenting study participants were re-assessed by research nurses or clinicians to determine 154 whether they still met all eligibility criteria, through repeat history taking and physical 155 examination. Eligible participants were admitted in hospital and an indwelling cannula was 156 inserted into a vein before their scheduled dose of ART and the first dose of the ACT.
157
Approximately 1 hour before the scheduled time of ART and ACT dosing, blood samples were 158 collected for haematological, renal and liver function tests and random glucose test.
160
Blood sample collection and processing 161 During hospitalization, blood samples for PK assays were collected in heparin tubes before 162 treatment and at 1, 2, 4, 6, 12, 24, 36, 48, 60 and 72 hours post treatment. After discharge, 163 blood samples were taken at 4, 5, 6, 7 and 14 days. Immediately after collection, the blood 164 samples were spun in a refrigerated centrifuge and the separated plasma samples were 165 temporarily frozen in liquid nitrogen before being transferred to a -80˚C freezer until PK 166 analyses.
168
Safety assessments 169 After the first dose of AL, blood samples were collected to detect haematological, renal and liver 170 function abnormalities at 12, 48 and 72 hrs and on day 7, 14, 21 and 28. In addition, in step 2, 171 12-lead electrocardiographs were performed pre-dosing, 5 hours after the first dose and 5 hours 172 after the last dose to determine QTc interval using the Fridericia QT correction formula (21). The 
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Characteristics of participants 219
In step 1, 26 participants were enrolled in the study; 24 participants were successfully followed 220 up for 28 days. Two participants taking NVP-based ART were discontinued from the study due 221 to protocol deviations and are not included in the analyses. In step 2, 40 of the 43 enrolled study 222 participants completed 28 days of follow-up. Three participants did not have sufficient data 223 points for PK characterization and are not included in the analyses. No participants were 224 enrolled in the NVP arm for step 2 on the advice of the DSMB because of the observed 225 haematological abnormalities in step 1. Supplementary Table 1 shows the baseline 226 characteristics of participants who completed follow-up in steps 1 and 2. In step 1, the median 227 duration of ART (in months) was significantly longer in the LPV/r group (63. 1, range [33.3-85 .0]) than in the EFV group (25.1, range [7.8-49.3] ) and the NVP group (58.8, range [24.7-80.6] ).
229
There were no major differences between baseline characteristics in step 1 or step 2.
231
Pharmacokinetics of lumefantrine and interactions with antiretroviral therapy in step 1 232 Table 1 summarizes the PK parameters in the study groups in step 1. Compared with the ART-233 naïve group, the geometric mean AUC 0-14 days of lumefantrine was 53% lower in the EFV-ART 234 group, 2.4 times higher in the NVP-ART group and 2.9 times higher in the LPV/r-based ART Table 2 summarizes the PK parameters in the study groups in step 2. The geometric mean 256 lumefantrine AUC 0-14 days was similar in the EFV-based ART group and the ART-naïve group.
257
Participants in the LPV/r-based ART group had an approximately 1.9 times higher geometric 258 mean AUC 0-14 days than those in the ART naïve group. There were no significant differences in 259 C max , t 1/2 and median t max in the EFV-and LPV/r-based ART groups compared to the ART-naïve 
304
Unlike in step 1, where lumefantrine exposure in the EFV-based ART group was significantly 306 lower in comparison to the ART-naïve group, overall lumefantrine exposure (AUC 0-14 days ) in step 307 2 was surprisingly not significantly different between the two groups. Lumefantrine 308 concentrations in the terminal elimination phase however, were consistently lower in the EFV-309 based ART group compared to the ART-naïve group in both steps (Figures 1a and 1b) . Since
310
EFV is a known inducer of CYP3A4 enzymes (9) 
319
There are conflicting published results on the PK interactions between AL and NVP-ART, with 320 studies suggesting higher (16, 28), lower (18, 24) or similar (17, 19) lumefantrine exposure in 321 those on AL and NVP-based ART compared to individuals on AL alone. This heterogeneity 322 potentially points to genetic variations in CYP activity across HIV-malaria endemic settings. We 323 found higher concentrations of lumefantrine in the NVP-based ART group in step 1 than in the 324 ART naïve group, consistent with findings from an earlier study in South Africa (16) and another 325 study conducted in Malawi and Uganda (28). There is evidence that NVP may increase 326 exposure of other drugs metabolised by the CYP3A4 results as shown with increased C max and 327 AUC of darunavir (29) and maraviroc (30), when co-administered with nevirapine, possibly due 328 to reduced metabolism secondary to competitive inhibition of metabolic enzymes (31) or as a 329 result of variations in availability of proteins to transport drugs (32). Thus, the increased AUC 0-14 days and C max of lumefantrine in the NVP-based ART group could suggest reduced CYP3A4-331 mediated metabolism or unavailability of proteins to transport lumefantrine. 332 333 Neutropenia has been previously documented when ACTs such as artesunate-amodiaquine 334 were administered among HIV infected children in Uganda (33). In addition, NVP is associated 335 with granulocytopenia as a marker of hypersensitivity (34) but its role in causing 336 thrombocytopenia has not been described. Thus, it is possible that neutropenia could occur 337 following co-administration of NVP and lumefantrine, as a result of increased lumefantrine 338 concentration, increased NVP concentrations or a synergistic effect of lumefantrine and NVP. In 339 our study population, the occurrence of neutropenia across all study groups in step 1, which 340 were not sustained at higher doses in step 2, is likely idiosyncratic. Apart from the underlying 341 HIV infection and with the exception of those on LPV/r-based ART who took it together with 342 zidovudine-ART, none of the participants who experienced thrombocytopenia had other 343 baseline predisposing factors, such as low immunity (CD4 <500 cells/mm 3 ) or low platelet count.
344
Nevertheless, the data and safety monitoring board recommended against administration of a 345 standard-dose adult course of AL with NVP due to the frequent occurrence of thrombocytopenia 346 in addition to neutropenia in the NVP group compared to the ART-naïve group in step 1. We, 347 therefore, were unable to investigate the effect of co-administration of a standard-dose adult 348 course of AL and NVP on the incidence of thrombocytopenia. 
355
(parasitaemia <135,000/μL) (46). In step 2 of this study, although participants on EFV-ART had lower day 7 lumefantrine concentrations than ART-naïve participants and those on LPV/r-based 357 ART had higher concentrations, the proportion achieving lumefantrine concentration ≥0.2 μg/mL 358 was only slightly lower in the EFV-ART group but was not significantly different from the ART-359 naïve group. This suggests that AL is still likely to be highly efficacious in those on EFV-based 360 ART, despite the PK interaction.
362
In this study, we did not assess impact of ART on plasma concentrations of the artemisinin 363 derivatives (artemether and its metabolite, dihydroartemisinin) which have a shorter half-life and 364 are crucial in clearing malaria parasites in the early phases of malaria treatment, because we 365 were interested in the longer acting drug, lumefantrine, which confers protection against 366 recrudescence following malaria infection (37, 47) . Additionally, we did not quantify NVP plasma 367 concentrations and were not able to assess any potential effect of lumefantrine on the steady-368 state concentration changes of NVP and subsequent impact on haematological changes.
369
Furthermore, this study was not designed to elucidate the mechanism of interaction between 
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